Cognitive impairment in patients who have had COVID-19, depending on the level of neurofilament

Cognitive deficit and the development of mental disorders are one of the important complications after a coronavirus disease, which in turn is manifested by depression, anxiety and panic attacks. Post-COVID-19 syndrome is the consequences of a coronavirus infection, in which up to 20% of people who have had a coronavirus infection suffer from long-term symptoms that last up to 12 weeks or more. Neurological complications after a COVID-19 disease, namely cognitive impairment, require further study, therefore there is a need to develop a predictive model for the development of cognitive impairment in patients who have had COVID-19.

References

1. Paterson R.W. et al. (2020) The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain, 143(10): 3104–3120. doi.org/10.1093/brain/awaa240.
2. Arlen R.K. (2007) New Research on Neurofilament Proteins. New York: Nova Science, 173 p.
3. Rothan H.A., Natekar J.P., Stone S. et al. (2021) Neuroinvasion and encephalitis following intranasal inoculation of SARS-CoV-2 in K18-hACE2 mice. Viruses, 13(1): 132. dx.doi.org/10.3390/v13010132.
4. Park Y., Kc N., Paneque A., Cole P.D. (2024) Tau, glial fibrillary acidic protein, and neurofilament light chain as brain protein biomarkers in cerebrospinal fluid and blood for diagnosis of neurobiological diseases. Int. J. Mol. Sci, 25(12): 6295. dx.doi.org/10.3390/ijms25126295.
5. Olsson B., Portelius E., Cullen N.C. et al. (2019) Association of cerebrospinal fluidneurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders. JAMA Neurol., 76(3): 318–325. DOI: 10.1001/jamaneurol.2018.3746.
6. Park Y., Kc N., Paneque A., Cole P.D. (2024) Tau, glial fibrillary acidic protein, and neurofilament light chain as brain protein biomarkers in cerebrospinal fluid and blood for diagnosis of neurobiological diseases. Int. J. Mol. Sci., 25(12): 6295. DOI: 10.3390/ijms25126295.
7. Gaetani L., Blennow K., Calabresi P. et al. (2017) Cerebrospinal fluid in neurologic disorders. Amsterdam, Elsevier, 146 p.
8. Bechter K., Brown D., Najjar S. (2019) Editorial: Recent Advances in Psychiatry From Psycho-Neuro-Immunology Research: Autoimmune Encephalitis, Autoimmune Encephalopathy, and Mild Encephalitis. Front. Psychiatr., 10: 169. doi.org/10.3389/ fpsyt.2019.00169.
9. Rawson T., Iosa M., Ricci F. et al. (2023) Coronavirus Disease (COVID-19): Pathophysiology, Epidemiology, Clinical Management and Public Health Response. Vol. II. Lausanne, Frontiers Media SA, 815 p.
10. Skripuletz T., Torkildsen O., Pul R., Sühs K.W. (2020) New Cerebrospinal Fluid Research to Uncover Mechanisms Driving Neurological and Psychiatric Diseases. Lausanne: Frontiers Media SA, 169 p.